Extended duration strategies for the pharmacologic treatment of diabetic retinopathy: current status and future prospects

Michael W. Stewart, Harry W Flynn, Stephen Schwartz, Ingrid U. Scott

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

Introduction: Intraocular pharmacotherapy (vascular endothelial growth factor [VEGF] inhibitors and corticosteroids) has become first-line therapy for diabetic retinopathy (DR). A series of intraocular injections is usually required before disease modulation decreases the treatment burden in some patients, but others with chronic diabetic macular edema may require intensive longer-term therapy. Areas covered: Recent studies showing successful pharmacologic treatment of proliferative DR will probably lead to increased use of pharmacotherapy, thereby further emphasizing the need for longer duration drugs. Recently approved anti-VEGF drugs (aflibercept) and corticosteroids (dexamethasone and fluocinolone inserts) provide extended durations of action. Longer action anti-VEGF molecules, sustained release devices and pumps, and encapsulated cell technology, may further decrease treatment burden, though regulatory approval may not occur for at least 5 years. Oral medications (danazol and minocycline) and modified topical drugs (loteprednol) will require daily administration but may decrease the frequency of visits to physicians’ offices. Intravitreally administered drugs that target different biochemical pathways are being developed as monotherapy and combination therapy, and their effects on durability remains to be seen. Expert opinion: The rich development pipeline promises to provide improved therapeutic options in addition to drugs and devices with longer duration of action.

Original languageEnglish (US)
Pages (from-to)1277-1287
Number of pages11
JournalExpert Opinion on Drug Delivery
Volume13
Issue number9
DOIs
StatePublished - Sep 1 2016

Fingerprint

Diabetic Retinopathy
Vascular Endothelial Growth Factor A
Pharmaceutical Preparations
Therapeutics
Adrenal Cortex Hormones
Intraocular Injections
Danazol
Drug Therapy
Physicians' Offices
Equipment and Supplies
Minocycline
Macular Edema
Expert Testimony
Dexamethasone
Technology

Keywords

  • Aflibercept
  • bevacizumab
  • corticosteroids
  • diabetic macular edema
  • ranibizumab
  • sustained release devices
  • vascular endothelial growth factor

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Extended duration strategies for the pharmacologic treatment of diabetic retinopathy : current status and future prospects. / Stewart, Michael W.; Flynn, Harry W; Schwartz, Stephen; Scott, Ingrid U.

In: Expert Opinion on Drug Delivery, Vol. 13, No. 9, 01.09.2016, p. 1277-1287.

Research output: Contribution to journalReview article

@article{88184db2bfc74039b4856032c6c786c6,
title = "Extended duration strategies for the pharmacologic treatment of diabetic retinopathy: current status and future prospects",
abstract = "Introduction: Intraocular pharmacotherapy (vascular endothelial growth factor [VEGF] inhibitors and corticosteroids) has become first-line therapy for diabetic retinopathy (DR). A series of intraocular injections is usually required before disease modulation decreases the treatment burden in some patients, but others with chronic diabetic macular edema may require intensive longer-term therapy. Areas covered: Recent studies showing successful pharmacologic treatment of proliferative DR will probably lead to increased use of pharmacotherapy, thereby further emphasizing the need for longer duration drugs. Recently approved anti-VEGF drugs (aflibercept) and corticosteroids (dexamethasone and fluocinolone inserts) provide extended durations of action. Longer action anti-VEGF molecules, sustained release devices and pumps, and encapsulated cell technology, may further decrease treatment burden, though regulatory approval may not occur for at least 5 years. Oral medications (danazol and minocycline) and modified topical drugs (loteprednol) will require daily administration but may decrease the frequency of visits to physicians’ offices. Intravitreally administered drugs that target different biochemical pathways are being developed as monotherapy and combination therapy, and their effects on durability remains to be seen. Expert opinion: The rich development pipeline promises to provide improved therapeutic options in addition to drugs and devices with longer duration of action.",
keywords = "Aflibercept, bevacizumab, corticosteroids, diabetic macular edema, ranibizumab, sustained release devices, vascular endothelial growth factor",
author = "Stewart, {Michael W.} and Flynn, {Harry W} and Stephen Schwartz and Scott, {Ingrid U.}",
year = "2016",
month = "9",
day = "1",
doi = "10.1080/17425247.2016.1198771",
language = "English (US)",
volume = "13",
pages = "1277--1287",
journal = "Expert Opinion on Drug Delivery",
issn = "1742-5247",
publisher = "Informa Healthcare",
number = "9",

}

TY - JOUR

T1 - Extended duration strategies for the pharmacologic treatment of diabetic retinopathy

T2 - current status and future prospects

AU - Stewart, Michael W.

AU - Flynn, Harry W

AU - Schwartz, Stephen

AU - Scott, Ingrid U.

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Introduction: Intraocular pharmacotherapy (vascular endothelial growth factor [VEGF] inhibitors and corticosteroids) has become first-line therapy for diabetic retinopathy (DR). A series of intraocular injections is usually required before disease modulation decreases the treatment burden in some patients, but others with chronic diabetic macular edema may require intensive longer-term therapy. Areas covered: Recent studies showing successful pharmacologic treatment of proliferative DR will probably lead to increased use of pharmacotherapy, thereby further emphasizing the need for longer duration drugs. Recently approved anti-VEGF drugs (aflibercept) and corticosteroids (dexamethasone and fluocinolone inserts) provide extended durations of action. Longer action anti-VEGF molecules, sustained release devices and pumps, and encapsulated cell technology, may further decrease treatment burden, though regulatory approval may not occur for at least 5 years. Oral medications (danazol and minocycline) and modified topical drugs (loteprednol) will require daily administration but may decrease the frequency of visits to physicians’ offices. Intravitreally administered drugs that target different biochemical pathways are being developed as monotherapy and combination therapy, and their effects on durability remains to be seen. Expert opinion: The rich development pipeline promises to provide improved therapeutic options in addition to drugs and devices with longer duration of action.

AB - Introduction: Intraocular pharmacotherapy (vascular endothelial growth factor [VEGF] inhibitors and corticosteroids) has become first-line therapy for diabetic retinopathy (DR). A series of intraocular injections is usually required before disease modulation decreases the treatment burden in some patients, but others with chronic diabetic macular edema may require intensive longer-term therapy. Areas covered: Recent studies showing successful pharmacologic treatment of proliferative DR will probably lead to increased use of pharmacotherapy, thereby further emphasizing the need for longer duration drugs. Recently approved anti-VEGF drugs (aflibercept) and corticosteroids (dexamethasone and fluocinolone inserts) provide extended durations of action. Longer action anti-VEGF molecules, sustained release devices and pumps, and encapsulated cell technology, may further decrease treatment burden, though regulatory approval may not occur for at least 5 years. Oral medications (danazol and minocycline) and modified topical drugs (loteprednol) will require daily administration but may decrease the frequency of visits to physicians’ offices. Intravitreally administered drugs that target different biochemical pathways are being developed as monotherapy and combination therapy, and their effects on durability remains to be seen. Expert opinion: The rich development pipeline promises to provide improved therapeutic options in addition to drugs and devices with longer duration of action.

KW - Aflibercept

KW - bevacizumab

KW - corticosteroids

KW - diabetic macular edema

KW - ranibizumab

KW - sustained release devices

KW - vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=84983261398&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983261398&partnerID=8YFLogxK

U2 - 10.1080/17425247.2016.1198771

DO - 10.1080/17425247.2016.1198771

M3 - Review article

C2 - 27293138

AN - SCOPUS:84983261398

VL - 13

SP - 1277

EP - 1287

JO - Expert Opinion on Drug Delivery

JF - Expert Opinion on Drug Delivery

SN - 1742-5247

IS - 9

ER -